Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2925 - Pamiparib, a Novel PARP 1/2 Inhibitor, Monotherapy for gBRCAm Patients with Recurrent Ovarian, Fallopian, and Primary Peritoneal Cancer: an Open-label, Multicenter, Phase 2 trial in China


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Genetic Testing and Counselling;  Clinical Research;  Targeted Therapy;  Genetic and Genomic Testing

Tumour Site

Ovarian Cancer


Xiaohua Wu


Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285


X. Wu1, J. Wang2, Q. Zhou3, T. Gu4, K. Zhang5, J. Liang6, S. Mu7, R. Ge8, H. Yang9, V. Huang10, R. Brachmann11, L. Wang12, M. Li4

Author affiliations

  • 1 Gynaecologic Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Gynaecologic Oncology, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 3 Chongqing Office For Cancer Control And Research, Chongqing Cancer Hospital, Chongqing/CN
  • 4 Medical Oncology, BeiGene (Beijing) Co. Ltd., Beijing/CN
  • 5 Biostatistics, BeiGene USA, Inc., Emeryville/US
  • 6 Clinical Biomarker, BeiGene (Beijing) Co. Ltd., Beijing/CN
  • 7 Clinical Pharmacology, BeiGene USA, Inc., Fort Lee/US
  • 8 Clinical research, BeiGene (Beijing) Co. Ltd., Beijing/CN
  • 9 Clinical Development, BeiGene (Shanghai) Co., Ltd., Shanghai/CN
  • 10 Medical Oncology, BeiGene USA, Inc., San Mateo/US
  • 11 Clinical Development, BeiGene USA, Inc., San Mateo/US
  • 12 China Development, BeiGene (Beijing) Co. Ltd., Beijing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2925


Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a class of antitumor agents that exert their cytotoxic effects by inhibiting PARP activity. PARPis are also capable of trapping PARP proteins complexes on damaged DNA, further augmenting cell death. Pamiparib is a selective PARP1/2 inhibitor with potent PARP trapping ability that can cross the blood-brain barrier and has demonstrated antitumor activity in both in vitro and in vivo nonclinical tumor models harboring BRCA gene mutations (BRCAmut) and other homologous recombination deficiencies. In Phase 1 studies (NCT02361723; NCT03333915), single-agent pamiparib was generally well tolerated and showed antitumor activity, notably in patients with high-grade non-mucinous ovarian cancer (HGOC). Antitumor activity was observed in patients with BRCA mutant and BRCA wild type ovarian cancers, whose tumors were either sensitive or had platinum-resistant disease. Data from these Phase 1 studies support the recommended Phase 2 pamiparib monotherapy dose of 60 mg PO BID.

Trial design

In this ongoing study of pamiparib in China (NCT03333915), patients with HGOC harboring germline BRCAmut who have received ≥2 prior lines of therapy are being enrolled in the Phase 2 part of the study. Patients with either platinum-sensitive (progression occurring ≥6 months after last dose of platinum) or platinum-resistant (progression occurring <6 months after last dose of platinum) HGOC are eligible. Germline BRCAmut status is identified or confirmed by central testing before enrollment. Approximately 100 patients with HGOC (platinum-sensitive, n = 80; platinum-resistant, n = 20) will receive pamiparib 60 mg PO BID until disease progression. The primary objective is to assess overall response rate according to RECIST v1.1; secondary objectives include assessment of pamiparib’s safety, tolerability, and pharmacokinetic profile. Evaluation of antitumor activity will include an estimation of overall and progression-free survival, as well as duration of clinical response.

Clinical trial identification


Legal entity responsible for the study

Beigene, Ltd.


Beigene, Ltd.

Editorial Acknowledgement

Medical writing and editorial support was provided by Regina Switzer, PhD (SuccinctChoice Medical Communications, Chicago, IL).


T. Gu, K. Zhang, J. Liang, S. Mu, R. Ge, H. Yang, V. Huang, R. Brachmann, L. Wang, M. Li: Employee: BeiGene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.